JPMorgan Upgrades Gap, Highlights Old Navy's Recent Success

Shares of Gap Inc (NYSE: GPS) look attractive at current levels after underperforming the S&P 500 index by 50% over the past three years, according to JPMorgan.

The Gap Analyst: Matthew Boss upgraded Gap's stock from Neutral to Overweight with a price target lifted from $22 to $30.

The Gap Thesis: Gap's Old Navy brand is standing out during the COVID-19 pandemic as it offers consumers a good value proposition on-par with off-price retailers, Boss said in a note. The brand has seen market share gains across key categories like denim and active as consumers are prioritizing value. Encouragingly, the brand faces an opportunity to win even more share from recent bankruptcies and eventual door closures.

See Also: Josh Brown Predicts Year-End Market Melt-Up, Bets On Reopening Stocks

Meanwhile, management's own "Power Plan 2023" strategy could prove to be conservative. The company is targeting a 10% EBIT margin target by fiscal 2023 and assumes Old Navy and Athleta account for around 70%. The math behind these assumptions assumes roughly break-even EBIT margins at Gap and Banana Republic, mid-teens EBIT margins at Old Navy (consistent with current levels), and high-teens EBIT margins at Athleta.

As such, Boss said buying the stock today implies investors are purchasing an "embedded call option" on the core Gap brand that could benefit from near-term catalysts. Most notably, the promotion with Kanye West for the YZY Gap launch in fiscal 2021 could accelerate adoption. This bullish outlook is further justified if a COVID-19 vaccine helps generate a rebound in workwear apparel.

GPS Price Action: Shares of Gap were trading higher by more than 7.7% at $26.27.

Photo credit: bargainmoose, Flickr

Latest Ratings for GPS

Nov 2020	JP Morgan	Upgrades	Neutral	Overweight
Nov 2020	Morgan Stanley	Maintains		Equal-Weight
Oct 2020	Morgan Stanley	Maintains		Equal-Weight

View More Analyst Ratings for GPS
View the Latest Analyst Ratings

See more from Benzinga

• Click here for options trades from Benzinga

• Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst

• BofA Upgrades United Rentals, Says COVID Vaccine A Potential 'Cure' For Industry

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.